McMaster University

Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial

Retrieved on: 
Tuesday, May 30, 2023

Pfizer Inc. (NYSE: PFE) today announced that the pivotal Phase 3 BASIS clinical trial ( NCT03938792 ) evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically meaningful effects.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced that the pivotal Phase 3 BASIS clinical trial ( NCT03938792 ) evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically meaningful effects.
  • “These results support the potential for marstacimab to become the first once-weekly non-factor treatment for people with hemophilia B and a treatment option that helps address the diverse needs of patients with hemophilia A or B without inhibitors.
  • The safety profile for marstacimab was consistent with Phase 1/2 results and treatment was generally well-tolerated.
  • Pfizer currently has three Phase 3 programs investigating novel treatment options for people living with hemophilia.

Dr. Kieran Murphy Presents Results of Clinical Trial Demonstrating Positive Effect Protecting DNA From Radiation Exposure

Retrieved on: 
Saturday, May 27, 2023

Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.

Key Points: 
  • Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.
  • During these high-intensity image-guided procedures, physicians were administered the antioxidant complex as two capsules, one hour prior to exposure.
  • Dr. Murphy's team has successfully demonstrated the protection of mitochondrial DNA from radiation in these subjects, marking a significant milestone in medical literature.
  • Considering that mitochondrial DNA is inherited maternally and is 13 times more vulnerable to radiation than nuclear DNA, this achievement holds tremendous promise.

Dr. Kieran Murphy Presents Results of Clinical Trial Demonstrating Positive Effect Protecting DNA From Radiation Exposure

Retrieved on: 
Saturday, May 27, 2023

Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.

Key Points: 
  • Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.
  • During these high-intensity image-guided procedures, physicians were administered the antioxidant complex as two capsules, one hour prior to exposure.
  • Dr. Murphy's team has successfully demonstrated the protection of mitochondrial DNA from radiation in these subjects, marking a significant milestone in medical literature.
  • Considering that mitochondrial DNA is inherited maternally and is 13 times more vulnerable to radiation than nuclear DNA, this achievement holds tremendous promise.

Dr. Kieran Murphy Presents Results of Clinical Trial Demonstrating Positive Effect Protecting DNA From Radiation Exposure

Retrieved on: 
Friday, May 26, 2023

Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.

Key Points: 
  • Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.
  • During these high-intensity image-guided procedures, physicians were administered the antioxidant complex as two capsules, one hour prior to exposure.
  • Dr. Murphy's team has successfully demonstrated the protection of mitochondrial DNA from radiation in these subjects, marking a significant milestone in medical literature.
  • Considering that mitochondrial DNA is inherited maternally and is 13 times more vulnerable to radiation than nuclear DNA, this achievement holds tremendous promise.

Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update

Retrieved on: 
Thursday, May 25, 2023

EDMONTON, Alberta, May 25, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the first quarter ended March 31, 2023.

Key Points: 
  • “Our team significantly advanced toward several key milestones related to new product development as well as strategic corporate initiatives.
  • Up to 96 subjects may be included in the study and dosages will escalate from 30 mg to 960 mg according to response.
  • Announced positive results from animal studies conducted by Angiogenesis Foundation on a wound healing model.
  • Financial Highlights for the First Quarter Ended March 31, 2023
    Total sales of $3,500,000 for the first quarter of 2023 compared to $6,172,000 for the comparative period in 2022.

Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases

Retrieved on: 
Tuesday, May 23, 2023

EDMONTON, Alberta, May 23, 2023 (GLOBE NEWSWIRE) --  Ceapro Inc.  (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced encouraging results from it’s completed pre-clinical CHRP study conducted with McMaster University evaluating PGX-processed yeast beta glucan (PGX-YBG) as a potential therapeutic option for individuals suffering from interstitial lung diseases (ILD).

Key Points: 
  • ILD damages the tissues between the small air sacs in the lungs (alveoli) and the blood vessels around them.
  • ILD represent a significant unmet medical need and is currently putting a major strain on healthcare systems around the globe.
  • Prior to the pandemic, Ceapro and accomplished researchers from McMaster University teamed up to develop a novel drug formulation for the potential treatment of IPF.
  • We are very encouraged by the results from this study showing that PGX-YBG has the ability of reprogramming macrophages to prevent fibrogenesis in mice.

Government of Canada supports project to improve awareness and reduce the risk of dementia in Canada

Retrieved on: 
Friday, May 26, 2023

Though dementia cannot be prevented and there is currently no cure, adopting healthy lifestyle behaviours can help reduce the risk.

Key Points: 
  • Though dementia cannot be prevented and there is currently no cure, adopting healthy lifestyle behaviours can help reduce the risk.
  • The Government of Canada is committed to supporting the more than 450,000 Canadians living with diagnosed dementia, their families, and caregivers.
  • We are also working with organizations across the country to increase awareness, reduce the risk of developing dementia, reduce stigma, and improve the quality of life of people living with dementia and their caregivers.
  • Since 2019, the Government of Canada has announced more than $300 million in funding that supports the national dementia strategy.

Brain Cancer Canada Awards CAD 80,000 Grant to Fund Innovative Glioblastoma Research

Retrieved on: 
Thursday, May 11, 2023

TORONTO, May 11, 2023 (GLOBE NEWSWIRE) -- Brain Cancer Canada, a leading charity dedicated to funding research and technology for breakthrough treatments for brain cancer patients, has awarded a CAD 80,000 research grant to Dr. Sheila Singh and her team at McMaster University.

Key Points: 
  • TORONTO, May 11, 2023 (GLOBE NEWSWIRE) -- Brain Cancer Canada, a leading charity dedicated to funding research and technology for breakthrough treatments for brain cancer patients, has awarded a CAD 80,000 research grant to Dr. Sheila Singh and her team at McMaster University.
  • “This seed funding from Brain Cancer Canada and its partners will allow us to advance our research, and help transform the treatment landscape for future glioblastoma patients.”
    Angela Scalisi, Chair of Brain Cancer Canada, highlights the need for more research funding in this area.
  • “We encourage the Canadian government to join us in investing in groundbreaking research that can lead to life-changing treatments for brain cancer patients.”
    This grant is the second of five Brain Cancer Canada will issue in May 2023 as part of the Gray in May brain cancer awareness month campaign.
  • By providing crucial funding for high-risk, high-reward projects like Dr. Singh's, Brain Cancer Canada aims to accelerate the development of new therapies and improve the lives of those affected by brain cancer.

We can uphold the solidarity created by COVID-19 even though WHO ended the international emergency

Retrieved on: 
Thursday, May 11, 2023

The World Heath Organization (WHO) has declared the end of the global emergency caused by the COVID-19 pandemic.

Key Points: 
  • The World Heath Organization (WHO) has declared the end of the global emergency caused by the COVID-19 pandemic.
  • Although COVID-19 remains a danger for many, especially with the possibility of new variants, experts are urging that we move forward to prepare for the next pandemic.
  • But the pandemic also created the circumstances for a type of global, national and local solidarity that has rarely been seen before.

Caremongering

    • A study led by researchers at McMaster University on caremongering Facebook groups found that the majority of posts were to request or offer materials like personal protective equipment, food and clothes or services like picking up groceries and prescriptions.
    • There was also a lot of information-sharing about COVID-19, community updates, inspiration and advice.

Pandemic unveiled systemic issues

    • Disasters like the pandemic provide an opportunity to examine the exception in order to understand the rule and to expose the unequal social structures that are often hidden in everyday life.
    • A University of Guelph study found that in 2020, as the reality of the pandemic set in, discussions in caremonger groups turned towards difficult topics of social justice, inequality and colonization.
    • One group organizer who took part in the study shared that she felt COVID-19 unveiled the challenges faced by marginalized people.

A more equitable post-pandemic world

    • As the global emergency ends, we need to ask ourselves how a post-pandemic world could be more equitable, just and nurturing.
    • The pandemic allowed people to connect with strangers in their neighbourhoods and country through the development of community good will across different geographies.
    • Pandemic travel restrictions also produced some positive environmental effects around the world.
    • As we reflect on the last three years, let us seize the opportunity to use the experience to create a more equitable, just and nurturing post-pandemic world.

Virtualware partners with Intuita to introduce VIROO in South Korea

Retrieved on: 
Thursday, May 4, 2023

BILBAO, Spain, May 04, 2023 (GLOBE NEWSWIRE) -- Spanish technology company Virtualware (EPA:MLVIR), one of the European leaders in the virtual reality industry, has inked a partnership agreement with Intuita to further introduce VIROO in South Korea.

Key Points: 
  • BILBAO, Spain, May 04, 2023 (GLOBE NEWSWIRE) -- Spanish technology company Virtualware (EPA:MLVIR), one of the European leaders in the virtual reality industry, has inked a partnership agreement with Intuita to further introduce VIROO in South Korea.
  • VIROO was a key focus for participants during a seminar for firefighters and safety professionals organized by Intuita in Daegu, South Korea, on 30 September 2022.
  • The aim of the seminar was to introduce technology trends in firefighting and safety, in particular how to build practical VR training environments.
  • “With multiple industries in Korea looking to use simulation technologies and VR/AR/MR solutions, the interest in these technologies is very high,” commented Sogu Yang, Managing Director of Intuita.